Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Array BioPharma Inc. buy stratec

Array BioPharma Inc.
Start price
€13.66
02.02.18 / 50%
Target price
€25.71
31.07.19
Performance (%)
216.05%
End price
€43.16
31.07.19
Summary
This prediction ended on 31.07.19 with a price of €43.16. With a performance of 216.05% the BUY prediction by stratec was a big success. stratec has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Array BioPharma Inc. - - - -
iShares Core DAX® -0,10 % 0,54 % 3,31 % 53,02 %
iShares Nasdaq 100 0,59 % -2,39 % 30,86 % 87,45 %
iShares Nikkei 225® -0,05 % -2,75 % 60,15 % 76,07 %
iShares S&P 500 0,94 % 1,29 % 23,99 % 70,01 %

Comments by stratec for this prediction

In the thread Array BioPharma Inc. diskutieren
Prediction Buy
Perf. (%) 216.05%
Target price 25.707
Change
Ends at 31.07.19

Array BioPharma combo a Breakthrough Therapy for type of colorectal cancer


  • Array BioPharma (NASDAQ:ARRY) is up 8% premarket on modest volume on the heels of its announcement that the FDA has designated the combination of BRAFTOVI (encorafenib), MEKTOVI (binimetinib) and Eli Lilly's (NYSE:LLY) ERBITUX (cetuximab) a Breakthrough Therapy for the treatment of patients with BRAF V600E mutation-positive metastatic colorectal cancer (mCRC) after the failure of one or two prior lines of treatment for metastatic cancer.




    • stratec 
    0
    Report Share
    02.02.18
    Prediction Buy
    Perf. (%) 216.05%
    Target price 25.707
    Change
    Ends at 31.07.19

    (Vom Mitglied beendet)

    stratec 
    0
    Report Share
    31.07.19